- May 20, 2016
Monarch Announces Groundbreaking EREI Technology
Remember our blog post regarding Estimated Residual Extracellular Insulin (EREI), which is similar in concept to “insulin on board” for subcutaneous insulin administration? As a refresher, EREI refers to residual insulin present in a patient’s body during intravenous insulin therapy that has potential for future activity affecting blood glucose levels.
This past Wednesday, the team at Monarch Medical Technologies announced their ground-breaking Estimated Residual Extracellular Insulin (EREI) technology for any hospital scenario where intravenous (IV) insulin is administered. Dr. Patrick Burgess, Founder and Inventor of EndoTool, described the technology as having the potential to nearly eliminate severe hypoglycemia while removing the risk of human oversight.
When a patient receives IV insulin in a hospital, they require a personalized dose based on the body’s response. A patient’s response to insulin is dependent on kidney function, current medical treatment, carbohydrates consumed (or not consumed), stress level, and amount of residual insulin present in their body. However, the calculations for an optimal insulin dose which account for all of this is too complex for a person to calculate on his or her own.
The software predicts and adjusts a patient’s subsequent insulin dose recommendation, and if a patient has more residual insulin than can be supported by circulating glucose, the software further adapts dosing recommendations.
To sum it up in one sentence: EndoTool IV provides confidence for the caregiver by achieving correct insulin dosing, maintaining glucose control, and avoiding hypoglycemia.
The full press release is available to view here.